Biogen revenue
Biogen's revenue was $9.89bn in fiscal 2025, up 2.2% on the year before. Since fiscal 2009 ($4.38bn) it has grown at a compound 5.2% a year. Over the last twelve months it was $10.30bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.4 | 4.7 | 5.0 | 5.5 | 6.9 | 9.7 | 10.8 | 11.4 | 12.3 | 13.5 | 14.4 | 13.4 | 11.0 | 10.2 | 9.8 | 9.7 | 9.9 | 10.3 |
| Growth on the year before | — | +7.7% | +7.0% | +9.3% | +25.7% | +40.0% | +10.9% | +6.4% | +7.2% | +9.6% | +6.9% | −6.5% | −18.3% | −7.4% | −3.3% | −1.6% | +2.2% | — |
| Gross profit | 4.0 | 4.3 | 4.6 | 5.0 | 6.1 | 8.5 | 9.5 | 10.0 | 10.6 | 11.6 | 12.4 | 11.6 | 8.9 | 7.9 | 7.3 | 7.4 | 7.5 | 7.6 |
| Gross margin | 91.3% | 91.5% | 90.8% | 90.1% | 87.6% | 87.9% | 88.5% | 87.1% | 86.7% | 86.5% | 86.4% | 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% | 74.0% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $7.1B | ▼ 1.3% |
| MS Product Revenues | $4B | ▼ 7.1% |
| Rare Disease Product Revenue | $2.2B | ▲ 8.4% |
| Revenues From Anti CD20 Therapeutic Programs | $1.9B | ▲ 6.3% |
| Tysabri Product | $1.7B | ▼ 2.9% |
| SPINRAZA | $1.5B | ▼ 1.7% |
| Fumarate | $1.4B | ▼ 10.6% |
| Royalty Attributed To OCREVUS | $1.4B | ▲ 5.6% |
| Interferon | $946M | ▼ 2.3% |
| VUMERITY | $747M | ▲ 18.9% |
| Contract Manufacturing Royalty and Other Revenue | $733M | ▲ 12.3% |
| Biosimilars | $729M | ▼ 8.1% |
| AVONEX | $696M | ▼ 1.7% |
| TECFIDERA | $680M | ▼ 29.7% |
| Contract Manufacturing and Other Revenue | $679M | ▲ 14.7% |
| SKYCLARYS | $521M | ▲ 36.1% |
| BENEPALI | $453M | ▼ 5.4% |
| PLEGRIDY | $250M | ▼ 4.0% |
| Other | $197M | ▲ 139.0% |
| ZURZUVAE | $195M | ▲ 170.2% |
| IMRALDI | $190M | ▼ 10.7% |
| Alzheimers Collaboration | $178M | ▲ 196.7% |
| QALSODY | $86.9M | ▲ 168.2% |
| Royalty | $53.5M | ▼ 11.6% |
| FLIXABI | $52.6M | ▼ 16.8% |
| BYOOVIZ | $32.4M | ▼ 11.5% |
| FUMADERM and ADUHELM | $2.1M | ▼ 79.6% |
| FAMPYRA | $1.4M | ▼ 98.0% |
| TOFIDENCE | $700,000 | ▼ 36.4% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Biogen's 10-K filed February 6, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Biogen | $10.30bn | 2.3% | 1.0% |
| Vertex Pharmaceuticals | $12.59bn | 10.2% | 9.8% |
| Regeneron Pharmaceuticals | $16.90bn | 18.6% | 8.9% |
| Incyte | $6.01bn | 24.9% | 18.5% |
| Argenx SE | $4.15bn | 89.9% | — |
| Neurocrine Biosciences Inc | $3.70bn | 38.0% | 27.5% |
Compare with peers
- Vertex Pharmaceuticals revenue
- Regeneron Pharmaceuticals revenue
- Incyte revenue
- Argenx SE revenue
- Neurocrine Biosciences Inc revenue
Head to head: BIIB vs VRTXBIIB vs REGNBIIB vs INCY
More: Biotechnology stocks compared, Health Care sector, rankings of US companies